Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration - 28/04/21
, L. Ruelle a, D. Konopnicki a, V.Y. Miendje Deyi b, N. Dauby aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 3 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Saccharomyces cerevisiae fungemia is a rare but life-threatening infection associated with probiotics containing S. boulardii. |
• | Mortality associated with fungemia was high (50%) |
• | Treatments used were fluconazole, voriconazole and echinocandin. |
• | Besides classical risk factors (ICU admission, central venous line) it seems that advanced age might be a contraindication for these probiotics. |
Abstract |
Saccharomyces cerevisiae fungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration.
Objective |
The aim of our study was to review cases of S. cerevisiae fungemia along with the corresponding risk factors (including S. boulardii probiotic intake), treatment and outcomes.
Patients and methods |
Retrospective study (2005-2017) of S. cerevisiae fungemia. All the data were extracted from medical files.
Results |
We identified 10 patients with S. cerevisiae fungemia. Mean age was 59.4 years (range 21-88). Four fifths (80%) were on total parenteral or enteral nutrition, 70% had a central venous line, and 30% were admitted in an Intensive Care Unit (ICU). S. boulardii-containing probiotic prescription was identified in 6 subjects. Three patients with no risk factors such as ICU or central venous catheter were 80 years old or more. Mortality rate was 50%.
Conclusion |
S. cerevisiae fungemia is a rare but life-threatening infection, associated with intake of probiotics containing S. boulardii. Besides classical risk factors, older age should be a contraindication for these probiotics.
Le texte complet de cet article est disponible en PDF.Keywords : Fungemia, Probiotics, Saccharomyces boulardii
Plan
Vol 51 - N° 3
P. 293-295 - mai 2021 Retour au numéro
Article précédent
- The vaccination coverage in dispensaries on Mayotte Island is lacking for natives and migrants alike
- C. Pascal, O. Lesens
- High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19
- A. Simonnet, I. Engelmann, A.-S. Moreau, B. Garcia, S. Six, A. El Kalioubie, L. Robriquet, D. Hober, M. Jourdain
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?